PAFAH1B1

Summary

Gene Symbol: PAFAH1B1
Description: platelet activating factor acetylhydrolase 1b regulatory subunit 1
Alias: LIS1, LIS2, MDCR, MDS, NudF, PAFAH, platelet-activating factor acetylhydrolase IB subunit alpha, lissencephaly 1 protein, platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 (45kDa), platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit (45kD), platelet-activating factor acetylhydrolase, isoform Ib, subunit 1 (45kDa)
Species: human

Top Publications

  1. ncbi Point mutations and an intragenic deletion in LIS1, the lissencephaly causative gene in isolated lissencephaly sequence and Miller-Dieker syndrome
    C Lo Nigro
    Laboratorio di Genetica Molecolare, San Raffaele Hospital, Milan, Italy
    Hum Mol Genet 6:157-64. 1997
  2. ncbi A heterozygous frameshift mutation in the Fanconi anemia C gene in familial T-ALL and secondary malignancy
    J R Rischewski
    University Children s Hospital, Hamburg, Germany
    Klin Padiatr 212:174-6. 2000
  3. ncbi A role for the lissencephaly gene LIS1 in mitosis and cytoplasmic dynein function
    N E Faulkner
    Department of Cell Biology University of Massachusetts Medical School, 377 Plantation Street, Worcester, Massachusetts 01605, USA
    Nat Cell Biol 2:784-91. 2000
  4. ncbi Miller-Dieker lissencephaly gene encodes a subunit of brain platelet-activating factor acetylhydrolase [corrected]
    M Hattori
    Department of Health Chemistry, Faculty of Pharmaceutical Sciences, University of Tokyo, Japan
    Nature 370:216-8. 1994
  5. ncbi Isolation of a Miller-Dieker lissencephaly gene containing G protein beta-subunit-like repeats
    O Reiner
    Institute for Molecular Genetics, Baylor College of Medicine, Houston, Texas 77030
    Nature 364:717-21. 1993
  6. pmc Reduction of microtubule catastrophe events by LIS1, platelet-activating factor acetylhydrolase subunit
    T Sapir
    Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
    EMBO J 16:6977-84. 1997
  7. ncbi LIS1 is a microtubule-associated phosphoprotein
    T Sapir
    Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel
    Eur J Biochem 265:181-8. 1999
  8. ncbi Hippocampal abnormalities and enhanced excitability in a murine model of human lissencephaly
    M W Fleck
    Laboratory of Cellular and Molecular Neurophysiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Neurosci 20:2439-50. 2000
  9. pmc The LIS1-related NUDF protein of Aspergillus nidulans interacts with the coiled-coil domain of the NUDE/RO11 protein
    V P Efimov
    University of Medicine and Dentistry or New Jersey, Robert Wood Johnson Medical School, Department of Pharmacology, 675 Hoes Lane, Piscataway, New Jersey 08854 5635, USA
    J Cell Biol 150:681-8. 2000
  10. ncbi LIS1 regulates CNS lamination by interacting with mNudE, a central component of the centrosome
    Y Feng
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Neuron 28:665-79. 2000

Research Grants

  1. Molecular Pathogenesis of MDS and CMML
    Jaroslaw P Maciejewski; Fiscal Year: 2013
  2. Jaroslaw P Maciejewski; Fiscal Year: 2014
  3. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Javier Pinilla; Fiscal Year: 2012
  4. Rafael Bejar; Fiscal Year: 2016
  5. Myelodysplastic Syndromes: Patterns of Care and Outcomes
    Xiaomei Ma; Fiscal Year: 2010
  6. Zhijian Qian; Fiscal Year: 2014
  7. Anjana Rao; Fiscal Year: 2016
  8. Camille Abboud; Fiscal Year: 2016
  9. Modeling Multi-step Leukemogenesis Nf1 and Kras Mutant Mice
    JENNIFER LAUCHLE; Fiscal Year: 2009
  10. BENJAMIN BRAUN; Fiscal Year: 2016

Detail Information

Publications354 found, 100 shown here

  1. ncbi Point mutations and an intragenic deletion in LIS1, the lissencephaly causative gene in isolated lissencephaly sequence and Miller-Dieker syndrome
    C Lo Nigro
    Laboratorio di Genetica Molecolare, San Raffaele Hospital, Milan, Italy
    Hum Mol Genet 6:157-64. 1997
    ..A gene containing beta-transducin like repeats, now known as LIS1, was previously mapped to the ILS/MDS chromosome region on 17p13.3...
  2. ncbi A heterozygous frameshift mutation in the Fanconi anemia C gene in familial T-ALL and secondary malignancy
    J R Rischewski
    University Children s Hospital, Hamburg, Germany
    Klin Padiatr 212:174-6. 2000
    ..increased risk to develop malignancies, especially Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). The risk for heterozygous individuals is not clear, epidemiological data are inconsistent...
  3. ncbi A role for the lissencephaly gene LIS1 in mitosis and cytoplasmic dynein function
    N E Faulkner
    Department of Cell Biology University of Massachusetts Medical School, 377 Plantation Street, Worcester, Massachusetts 01605, USA
    Nat Cell Biol 2:784-91. 2000
    Mutations in the LIS1 gene cause gross histological disorganization of the developing human brain, resulting in a brain surface that is almost smooth...
  4. ncbi Miller-Dieker lissencephaly gene encodes a subunit of brain platelet-activating factor acetylhydrolase [corrected]
    M Hattori
    Department of Health Chemistry, Faculty of Pharmaceutical Sciences, University of Tokyo, Japan
    Nature 370:216-8. 1994
    ..Our results raise the possibility that PAF and PAF acetylhydrolase are important in the formation of the brain cortex during differentiation and development...
  5. ncbi Isolation of a Miller-Dieker lissencephaly gene containing G protein beta-subunit-like repeats
    O Reiner
    Institute for Molecular Genetics, Baylor College of Medicine, Houston, Texas 77030
    Nature 364:717-21. 1993
    ..The deduced amino-acid sequence shows significant homology to beta-subunits of heterotrimeric G proteins, suggesting that it could possibly be involved in a signal transduction pathway crucial for cerebral development...
  6. pmc Reduction of microtubule catastrophe events by LIS1, platelet-activating factor acetylhydrolase subunit
    T Sapir
    Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
    EMBO J 16:6977-84. 1997
    ..Previous studies have shown that LIS1, the defective gene found in patients with lissencephaly, is a subunit of the platelet-activating factor ..
  7. ncbi LIS1 is a microtubule-associated phosphoprotein
    T Sapir
    Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel
    Eur J Biochem 265:181-8. 1999
    Lissencephaly, a severe brain malformation, may be caused by mutations in the LIS1 gene. LIS1 encodes a microtubule-associated protein (MAP) that is also part of the enzyme complex, platelet-activating factor acetylhydrolase...
  8. ncbi Hippocampal abnormalities and enhanced excitability in a murine model of human lissencephaly
    M W Fleck
    Laboratory of Cellular and Molecular Neurophysiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Neurosci 20:2439-50. 2000
    ..and heterotopia throughout the granule cell and pyramidal cell layers of mice containing a heterozygous deletion of Lis1, a mouse model of human 17p13.3-linked lissencephaly...
  9. pmc The LIS1-related NUDF protein of Aspergillus nidulans interacts with the coiled-coil domain of the NUDE/RO11 protein
    V P Efimov
    University of Medicine and Dentistry or New Jersey, Robert Wood Johnson Medical School, Department of Pharmacology, 675 Hoes Lane, Piscataway, New Jersey 08854 5635, USA
    J Cell Biol 150:681-8. 2000
    The nudF gene of the filamentous fungus Aspergillus nidulans acts in the cytoplasmic dynein/dynactin pathway and is required for distribution of nuclei...
  10. ncbi LIS1 regulates CNS lamination by interacting with mNudE, a central component of the centrosome
    Y Feng
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Neuron 28:665-79. 2000
    b>LIS1, a microtubule-associated protein, is required for neuronal migration, but the precise mechanism of LIS1 function is unknown...
  11. pmc Role of dynein, dynactin, and CLIP-170 interactions in LIS1 kinetochore function
    Chin Yin Tai
    University of Massachusetts Medical School, Department of Cell Biology, Worcester, MA 01605, USA
    J Cell Biol 156:959-68. 2002
    Mutations in the human LIS1 gene cause type I lissencephaly, a severe brain developmental disease involving gross disorganization of cortical neurons. In lower eukaryotes, LIS1 participates in cytoplasmic dynein-mediated nuclear migration...
  12. pmc LIS1, CLIP-170's key to the dynein/dynactin pathway
    Frédéric M Coquelle
    Institut Curie, Section de Recherche, CNRS UMR 146, Centre Universitaire d Orsay, 91405 Orsay Cedex, France
    Mol Cell Biol 22:3089-102. 2002
    ..b>LIS1, a protein implicated in brain development, acts in several processes mediated by the dynein/dynactin pathway by ..
  13. pmc Human Nudel and NudE as regulators of cytoplasmic dynein in poleward protein transport along the mitotic spindle
    Xiumin Yan
    Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
    Mol Cell Biol 23:1239-50. 2003
    ..evidence supports the idea that a signaling pathway containing orthologs of at least mammalian NudE and Nudel, Lis1, and cytoplasmic dynein is conserved for eukaryotic nuclear migration...
  14. pmc Nudel functions in membrane traffic mainly through association with Lis1 and cytoplasmic dynein
    Yun Liang
    Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China
    J Cell Biol 164:557-66. 2004
    Nudel and Lis1 appear to regulate cytoplasmic dynein in neuronal migration and mitosis through direct interactions. However, whether or not they regulate other functions of dynein remains elusive...
  15. pmc Lis1 and doublecortin function with dynein to mediate coupling of the nucleus to the centrosome in neuronal migration
    Teruyuki Tanaka
    Department of Neurosciences, University of California, San Diego, La Jolla 92093 0624, USA
    J Cell Biol 165:709-21. 2004
    Humans with mutations in either DCX or LIS1 display nearly identical neuronal migration defects, known as lissencephaly. To define subcellular mechanisms, we have combined in vitro neuronal migration assays with retroviral transduction...
  16. pmc LIS1 RNA interference blocks neural stem cell division, morphogenesis, and motility at multiple stages
    Jin Wu Tsai
    Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Cell Biol 170:935-45. 2005
    Mutations in the human LIS1 gene cause the smooth brain disease classical lissencephaly...
  17. pmc LIS1 and NDEL1 coordinate the plus-end-directed transport of cytoplasmic dynein
    Masami Yamada
    Department of Genetic Disease Research, Osaka City University Graduate School of Medicine, Osaka, Japan
    EMBO J 27:2471-83. 2008
    b>LIS1 was first identified as a gene mutated in human classical lissencephaly sequence. LIS1 is required for dynein activity, but the underlying mechanism is poorly understood...
  18. doi Opposing effects of Ndel1 and alpha1 or alpha2 on cytoplasmic dynein through competitive binding to Lis1
    Chong Ding
    Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
    J Cell Sci 122:2820-7. 2009
    b>Lis1 is an essential protein whose insufficiency causes aberrant neuronal positioning during neocortical development...
  19. doi Functional interplay between LIS1, NDE1 and NDEL1 in dynein-dependent organelle positioning
    Connie Lam
    Faculty of Life Sciences, University of Manchester, Manchester, M13 9PT, UK
    J Cell Sci 123:202-12. 2010
    b>LIS1, NDE1 and NDEL1 modulate cytoplasmic dynein function in several cellular contexts. However, evidence that they regulate dynein-dependent organelle positioning is limited...
  20. doi The human LIS1 is downregulated in hepatocellular carcinoma and plays a tumor suppressor function
    Zhen Xing
    State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, PR China
    Biochem Biophys Res Commun 409:193-9. 2011
    The human lissencephaly-1 gene (LIS1) is a disease gene responsible for Miller-Dieker lissencephaly syndrome (MDL). LIS1 gene is located in the region of chromosome 17p13...
  21. pmc Mutually exclusive cytoplasmic dynein regulation by NudE-Lis1 and dynactin
    Richard J McKenney
    Department of Pathology and Cell Biology, Columbia University, New York, New York 10032, USA
    J Biol Chem 286:39615-22. 2011
    ..Together these results reveal an unanticipated mechanism for preventing dual regulation of individual dynein molecules, and identify the IC as a nexus for regulatory interactions within the dynein complex...
  22. pmc High-resolution imaging reveals indirect coordination of opposite motors and a role for LIS1 in high-load axonal transport
    Julie Y Yi
    Department of Pathology and Cell Biology, Columbia University, New York, NY 10027, USA
    J Cell Biol 195:193-201. 2011
    ..Acute LIS1 inhibition or LIS1 RNA interference had little effect on lysosomes/late endosomes but severely inhibited axonal ..
  23. ncbi The lissencephaly gene product Lis1, a protein involved in neuronal migration, interacts with a nuclear movement protein, NudC
    S M Morris
    Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Curr Biol 8:603-6. 1998
    ..Miller-Dieker syndrome (MDS) or isolated lissencephaly sequence (ILS) have a hemizygous deletion or mutation in the LIS1 gene [3,6]; both conditions are characterized by a smooth cerebral surface, a thickened cortex with four abnormal ..
  24. ncbi Lissencephaly associated mutations suggest a requirement for the PAFAH1B heterotrimeric complex in brain development
    K J Sweeney
    Max Planck Institute for Experimental Endocrinology, Feodor Lynen Strasse 7, D 30625, Hannover, Germany
    Mech Dev 92:263-71. 2000
    ..MDS and ILS patients have a hemizygous deletion or mutation in the LIS1 gene (PAFAH1B1), therefore, the LIS1 encoded protein (Lis1) may play a role in neuronal migration...
  25. ncbi NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein
    M Niethammer
    Department of Pathology, Harvard Medical School, 200 Longwood Avenue, Boston, Massachussetts 02115, USA
    Neuron 28:697-711. 2000
    Disruption of one allele of the LIS1 gene causes a severe developmental brain abnormality, type I lissencephaly...
  26. ncbi Clinical and molecular basis of classical lissencephaly: Mutations in the LIS1 gene (PAFAH1B1)
    Carlos Cardoso
    Department of Human Genetics, University of Chicago, Chicago, Illinois, USA
    Hum Mutat 19:4-15. 2002
    ..3. This gene encodes the LIS1 or PAFAH1B1 protein with a coiled-coil domain at the N-terminus and seven WD40 repeats at the C-terminus...
  27. ncbi 14-3-3epsilon is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome
    Kazuhito Toyo-oka
    Department of Pediatrics, UCSD Cancer Center, University of California, San Diego School of Medicine, 9500 Gilman Drive, Mailstop 0627, La Jolla, California 92093 0627, USA
    Nat Genet 34:274-85. 2003
    ..Mutations in PAFAH1B1 (the gene encoding LIS1) are responsible for ILS and contribute to MDS, but the genetic causes of the greater ..
  28. ncbi LIS1 missense mutations: variable phenotypes result from unpredictable alterations in biochemical and cellular properties
    Michal Caspi
    Department of Molecular Genetics, Weizmann Institute of Science, 76100 Rehovot, Israel
    J Biol Chem 278:38740-8. 2003
    Mutations in one allele of the human LIS1 gene cause a severe brain malformation, lissencephaly. Although most LIS1 mutations involve deletions, several point mutations with a single amino acid alteration were described...
  29. pmc HIV-1 Tat interacts with LIS1 protein
    Nicolas Epie
    Center for Sickle Cell Disease, Howard University, Washington, DC 20059, USA
    Retrovirology 2:6. 2005
    ..Tat-induced apoptosis of T-cells is attributed, in part, to the distortion of microtubules polymerization. LIS1 is a microtubule-associated protein that facilitates microtubule polymerization.
  30. ncbi Subcortical band heterotopia in rare affected males can be caused by missense mutations in DCX (XLIS) or LIS1
    D T Pilz
    Institute for Medical Genetics, University Hospital of Wales, Cardiff CF4 4XW, UK
    Hum Mol Genet 8:1757-60. 1999
    ..We have now identified mutations in either the DCX or LIS1 gene in three of 11 boys studied, demonstrating for the first time that mutations of either DCX or LIS1 can cause ..
  31. ncbi Interaction between LIS1 and doublecortin, two lissencephaly gene products
    M Caspi
    Department of Molecular Genetics, Weizmann Institute of Science, 76100 Rehovot, Israel
    Hum Mol Genet 9:2205-13. 2000
    Mutations in either LIS1 or DCX are the most common cause for type I lissencephaly. Here we report that LIS1 and DCX interact physically both in vitro and in vivo...
  32. pmc Lissencephaly gene product. Localization in the central nervous system and loss of immunoreactivity in Miller-Dieker syndrome
    M Mizuguchi
    Department of Mental Retardation and Birth Defect Research, National Institute of Neuroscience, NCNP, Tokyo, Japan
    Am J Pathol 147:1142-51. 1995
    ..These results are consistent with the notion that a deficiency of LIS-1 protein is the direct cause of the brain malformation and that the protein plays a critical role in neuronal migration...
  33. ncbi NudC associates with Lis1 and the dynein motor at the leading pole of neurons
    J P Aumais
    Department of Molecular Biology, Baylor College of Medicine, and M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Neurosci 21:RC187. 2001
    ..Mammalian NudC interacts with Lis1, a neuronal migration protein important during neocorticogenesis, suggesting a conserved mechanism of nuclear ..
  34. ncbi [Erythropoietin: biochemical characteristics, biologic effects, indications and results of use in hematology]
    A M Marmont
    II Divisione di Ematologia, Ospedale San Martino, Genova, Italy
    Tumori 83:S3-15. 1997
    ..clonal anemia, such as paroxysmal nocturnal hemoglobinuria (PNH), hemoglobinopaties, myelodysplastic syndromes (MDS) and others...
  35. ncbi The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents
    B Breuer
    Medical Research Department, The Jewish Home and Hospital, New York, NY 10025, USA
    Women Health 31:71-85. 2000
    ..PARTICIPANTS: 93,031 women, at least 65 years old, whose data were part of the 1993 New York State MDS, and for whom there was documentation of treatment with at least one medication...
  36. ncbi Pain and cognitive status among nursing home residents in Canada
    W R Proctor
    Department of Health Studies and Gerontology, University of Waterloo, Ontario, Canada
    Pain Res Manag 6:119-25. 2001
    ..DESIGN: The study is based on a secondary analysis of data collected with the minimum data set (MDS 2.0)...
  37. ncbi [Prevention of infections in a case with myelodysplastic syndrome by an intermittent subcutaneous administration of G-CSF]
    Y Saburi
    Department of Internal Medicine, Almeida Hospital of Oita City Medical Association, Japan
    Kansenshogaku Zasshi 70:506-11. 1996
    ..on these findings the diagnosis of refractory anemia with excess of blasts (RAEB) of the myelodysplastic syndrome (MDS) was made and therapy with low dose Cytarabine (Ara-C) was initiated in April 1993...
  38. ncbi [Clinical efficacy of lomefloxacin for associated infection in patients with hematological diseases]
    T Suzuki
    Division of Hematology, Shiga Medical Center for Adult Diseases
    Kansenshogaku Zasshi 71:143-52. 1997
    ..As myelodysplastic syndrome (MDS), four infection-bearing patients and five patients with prophylactic usage were analyzed...
  39. ncbi Familial partial monosomy 7 and myelodysplasia: different parental origin of the monosomy 7 suggests action of a mutator gene
    A Minelli
    Biologia Generale e Genetica Medica, , C.P. 217, I 27100, Pavia, Italy
    Cancer Genet Cytogenet 124:147-51. 2001
    Two sisters are reported, both with a myelodysplastic syndrome (MDS) associated with partial monosomy 7...
  40. ncbi [Abnormalities of the p53, N-ras, DCC and FLT-3 genes in myelodysplastic syndromes]
    K Nakamura
    Department of 3rd Internal Medicine, Nippon Medical School, Tokyo, Japan
    J Nippon Med Sch 68:143-8. 2001
    ..of the deleted in colorectal carcinoma (DCC) gene were analyzed in 59 patients with myelodysplastic syndromes (MDS). Mutations of N-ras, p53, and FLT-3 genes were detected in 7, 7, 1 of the 59 patients with MDS, respectively...
  41. ncbi Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms
    Vesna Najfeld
    Department of Pathology, Tumor Cytogenetics Laboratory, The Mount Sinai School of Medicine, New York, NY 10029, USA
    Exp Hematol 35:1668-76. 2007
    ....
  42. ncbi [Study on the transformation from myelodysplastic syndromes into acute leukemias]
    J Shi
    Institute of Hematology and Blood Disease Hospital, CAMS and PUMC, Tianjin 300020, China
    Zhonghua Xue Ye Xue Za Zhi 22:351-4. 2001
    OBJECTIVE: To study the patterns of transformation from myelodysplastic syndromes (MDS) into acute leukemias (AL)...
  43. doi Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden
    Erica D Warlick
    Blood and Marrow Transplant Program, Departments of Medicine and Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 15:30-8. 2009
    Allogeneic stem cell transplantation is the only known curative therapy for myelodysplastic syndromes (MDS)...
  44. ncbi Cytomembranous inclusions in myelodysplastic syndrome
    J G Guccion
    Laboratory Service, Department of Veterans Affairs Medical Center, Washington, DC 20422
    Ultrastruct Pathol 16:521-7. 1992
    ..presented with fever of unknown origin and peripheral blood and bone marrow findings of myelodysplastic syndrome (MDS): refractory anemia with an excess of blasts in transformation that subsequently progressed to acute myeloblastic ..
  45. ncbi t(1;7) in acute myeloblastic leukemia following myelodysplastic syndrome (RAEB-T)
    R Defferrari
    Cattedra di Biologia Generale R, Genova, Italia
    Tumori 74:555-8. 1988
    A case is described of myelodysplastic syndrome (MDS) refractory anemia type with an excess of blasts in transformation with early leukemic evolution (AML-M1). All bone marrow cells examined showed an unbalanced translocation t(1;7)...
  46. ncbi Molecular typing of methicillin-resistant Staphylococcus aureus in a university teaching hospital
    T Ishimoto
    Department of Clinical Microbiology and Immunology, School of Allied Health Sciences, Tokyo Medical and Dental University, Japan
    Kansenshogaku Zasshi 73:225-32. 1999
    ..Strains which harboured a single plasmid of approximately 13.4 Mds in molecular weight were the most numerous (55.7% of the isolates)...
  47. ncbi Ocular complications in myelodysplastic syndromes as preleukemic disorders
    Takeshi Kezuka
    Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan
    Jpn J Ophthalmol 49:377-83. 2005
    To identify ocular complications in patients with myelodysplastic syndromes (MDS), who have a propensity to progress to acute myeloid leukemia (AML).
  48. ncbi A multivariate fall risk assessment model for VHA nursing homes using the minimum data set
    Dustin D French
    VISN 8 Patient Safety Center of Inquiry, James A Haley VAMC, Tampa, FL 33612, USA
    J Am Med Dir Assoc 8:115-22. 2007
    The purpose of this study was to develop a multivariate fall risk assessment model beyond the current fall Resident Assessment Protocol (RAP) triggers for nursing home residents using the Minimum Data Set (MDS).
  49. ncbi Predictors of rehabilitation outcomes: a comparison of Israeli and Italian geriatric post-acute care (PAC) facilities using the minimum data set (MDS)
    Jacob Gindin
    Geriatric Institute for Education and Research, Kaplan Medical Center, Rehovot, Israel
    J Am Med Dir Assoc 8:233-42. 2007
    ..To understand the relative contribution of sociodemographic, clinical, and health care features to rehabilitation outcomes in Israel and in Italy in post-acute care (PAC) facilities...
  50. ncbi Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group
    A F Remacha
    Hospital de Sant Pau, Hematology Department, Avda Padre Claret 167, Barcelona 08025, Spain
    Haematologica 84:1058-64. 1999
    Anemia leading to transfusion is probably the most important problem in patients with myelodysplastic syndromes (MDS)...
  51. ncbi [A case of myelodysplastic syndrome who died of septic pulmonary embolism]
    A Nakamura
    First Department of Internal Medicine, Nagoya City University Medical School
    Kansenshogaku Zasshi 69:835-9. 1995
    A case of myelodysplastic syndrome (MDS) complicated by septic pulmonary embolism is reported. A 61-year-old female who had been followed for refractory anemia with excess of blasts suddenly died of acute respiratory failure...
  52. ncbi Myelodysplastic syndromes: the pediatric point of view
    F Locatelli
    Clinica Pediatrica, Universita di Pavia, IRCCS Policlinico San Matteo, Italy
    Haematologica 80:268-79. 1995
    Myelodysplastic syndromes (MDS) are clonal disorders of the multipotent hematopoietic stem cell characterized by ineffective hematopoiesis and associated with marrow hypercellularity, increased intramedullary cell death and peripheral ..
  53. ncbi The review process used by US health care plans to evaluate new medical technology for coverage
    C A Steiner
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Gen Intern Med 11:294-302. 1996
    OBJECTIVE: To examine the process and information used by medical directors (MDs) of private health plans to make medical coverage determinations for new medical technologies, and to assess the influence of plan characteristics on the ..
  54. ncbi [Not Available]
    M H Bickel
    Medizinhistorisches Institut, Bern, Switzerland
    NTM 8:129-48. 2000
    ..A number of them were active in two countries due to emigration from fascist Europe in the 1930s. All were MDs except for one historian...
  55. ncbi Surface marker abnormalities in myelodysplastic syndromes
    M T Elghetany
    Department of Pathology, University of Texas Medical Branch, Galveston 77555 0743, USA
    Haematologica 83:1104-15. 1998
    The myelodysplastic syndromes (MDS) are clonal stem cell disorders associated with a variety of abnormalities of mature and maturing cells, including surface antigen abnormalities...
  56. doi Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms
    Mariangela Greco
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Roma, Italy
    Blood Cells Mol Dis 45:181-5. 2010
    ..tumor suppressor genes, with a pathogenetic role in tumor development and progression in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)...
  57. doi Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience
    Suhag H Parikh
    Division of Pediatric Blood and Marrow Transplantation, Duke University Medical Center, Durham, North Carolina 27705, USA
    Biol Blood Marrow Transplant 15:948-55. 2009
    Myelodysplastic syndromes (MDS) respond poorly to chemotherapy. Between 1995 and 2006, 23 pediatric patients with MDS were transplanted with unrelated donor umbilical cord blood (UUCB) at our center. The median age was 11...
  58. ncbi Bestatin treatment of myelodysplastic syndromes (MDS) and the effects of bestatin on hematopoiesis in MDS
    Y Uzuka
    Third Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan
    Acta Oncol 29:803-7. 1990
    ..The results suggest that bestatin has an enhancing effect on burst promoting activity production of helper (CD4 positive) T lymphocytes and the effect on hematopoiesis of bestatin may be mediated by T lymphocytes...
  59. ncbi Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis
    He Qi
    Hematology Department, Shanghai Sixth Hospital of Shanghai Jiaotong University, Shanghai, PR China
    Ann Hematol 85:95-101. 2006
    ..growth factor receptor (IGF-IR) and its impact on hematopoietic cells apoptosis in myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML), marrow samples from 16 patients with MDS and 16 patients with AML were examined ..
  60. doi Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial
    Myrna Candelaria
    Division de Investigación Clínica, Instituto Nacional de Cancerología INCan, Mexico City, Mexico
    Ann Hematol 90:379-87. 2011
    ..two DNA methyltransferase (DNMT) inhibitors, are the current standard of treatment for myelodysplastic syndrome (MDS). Histone deacetylase (HDAC) inhibitors are also being tested against MDS...
  61. ncbi Clinical implications of immunophenotypic abnormalities of bone marrow myeloid cell compartment in myelodysplastic syndromes
    D Marisavljevic
    Medical Center Bezanijska kosa, Department of Hematology, Belgrade, Serbia
    J BUON 15:746-52. 2010
    to evaluate the biological and clinical implications of immunophenotypic abnormalities of bone marrow myeloid cell compartment in patients with primary myelodysplastic syndromes (MDS).
  62. ncbi Intensive chemotherapy for patients with high-risk myelodysplastic syndrome
    M Beran
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, 77030, USA
    Int J Hematol 72:139-50. 2000
    ..induces complete remission in approximately half of patients with high-risk (HR) myelodysplastic syndrome (MDS)...
  63. ncbi Basal ganglia abnormalities in tardive dyskinesia. Possible relationship with duration of neuroleptic treatment
    P Dalgalarrondo
    Neurobiology Unit, Central Institute of Mental Health, Mannheim, Germany
    Eur Arch Psychiatry Clin Neurosci 244:272-7. 1994
    ..CT data were analyzed using two multivariate statistical methods [multidimensional scaling (MDS) and step-wise discriminant analysis]...
  64. doi Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments
    Heather A Leitch
    Division of Hematology, St Paul s Hospital and the University of British Columbia, 440 1144 Burrard Street, Vancouver, BC, Canada
    Drugs 71:155-77. 2011
    The myelodysplastic syndromes (MDS) are characterized by cytopenias and risk of progression to acute myeloid leukaemia (AML)...
  65. ncbi Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes
    Gurveen Saberwal
    MDS Center and Section of Myeloid Diseases, Rush Presbyterian St Luke s Medical Center, Rush University, Chicago, IL 60612, USA
    J Hematother Stem Cell Res 12:443-50. 2003
    ..in S-phase cells is characteristically found in the bone marrow (BM) of patients with myelodysplastic syndromes (MDS)...
  66. ncbi Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes
    S D Mundle
    Rush Cancer Institute, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Am J Hematol 60:36-47. 1999
    ..levels of tumor necrosis factor-alpha (TNF-alpha) in the bone marrows of patients with myelodysplastic syndromes (MDS), using histochemical techniques...
  67. ncbi Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone
    P Musto
    Department of Onco Hematology, Unit of Hematology, IRCCS Casa Sollievo della Sofferenza, 71013 S Giovanni Rotondo, Italy
    Haematologica 86:44-51. 2001
    Recombinant erythropoietin (r-EPO) induces erythroid responses in patients affected by myelodysplastic syndromes (MDS). However, the response rate declines to 10-15% in MDS with substantial transfusion needs...
  68. ncbi Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis
    K Ohshima
    Department of Pathology, School of Medicine, Fukuoka University, Nanakuma 7 45 1, Jonanku, Fukuoka 814 01, Japan
    Leuk Lymphoma 44:1339-46. 2003
    The myelodysplastic syndromes (MDS) are a group of disorders characterized by peripheral pancytopenia despite normo- or hyper-cellular bone marrow...
  69. ncbi Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes
    S D Mundle
    Rush Cancer Institute, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Cancer Lett 140:201-7. 1999
    ..of hematopoietic cells is thought to contribute to the ineffective hematopoiesis in myelodysplastic syndromes (MDS)...
  70. ncbi [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA]
    Ji Ying Su
    Department of Hematology, Shanghai Sixth People Hospital, Shanghai Jiaotong University, Shanghai 200233, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 17:459-63. 2009
    ..homoharringtonine, cytarabine and granulocyte colony-stimulating factor (G-CSF)) on the patients with high-risk MDS or MDS-transformed acute myeloid leukemia...
  71. ncbi Molecular genetic aspects of myelodysplastic syndromes
    C R Bartram
    Department of Pediatrics II, University of Ulm, Germany
    Hematol Oncol Clin North Am 6:557-70. 1992
    ..Two genomic alterations associated with MDS have been analyzed in more detail...
  72. ncbi The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia
    Jaroslav Cermak
    Institute of Hematology and Blood Transfusion, Prague, Czech Republic
    Leuk Res 29:371-9. 2005
    ..obtained from bone marrow and peripheral blood of 36 female patients with primary myelodysplastic syndrome (MDS)...
  73. ncbi Is drug therapy for urinary incontinence used optimally in long-term care facilities?
    Siva Narayanan
    Beverly Enterprises, Fort Smith, AR, USA
    J Am Med Dir Assoc 8:98-104. 2007
    ..To examine the management of urinary incontinence (UI) among nursing home (NH) residents in the United States, particularly drug therapy for UI in those who may be suitable candidates for such treatment based on their functional status...
  74. ncbi In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis
    Yann Erick Claessens
    Department of Hematology, AP HP, Hopital Cochin, Paris, France
    Blood 99:1594-601. 2002
    ..Ineffective erythropoiesis is a common feature of myelodysplastic syndromes (MDS). We used a 2-step liquid-culture procedure to study erythropoiesis in MDS...
  75. ncbi Anti-erythroblast autoimmunity in early myelodysplastic syndromes
    Wilma Barcellini
    Dipartimento di Ematologia, Padiglione Granelli, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy
    Haematologica 92:19-26. 2007
    Autoimmune phenomena, mainly directed against red blood cells are described in myelodysplastic syndromes (MDS), particularly early MDS, i.e. refractory anemia (RA) and RA with ringed sideroblasts (RARS)...
  76. ncbi Myelodysplastic syndromes--a population-based study on transformation and survival
    P Hörnsten
    Department of Medicine, Umea University Hospital, Sweden
    Acta Oncol 34:473-8. 1995
    A retrospective analysis was done on 113 patients (median age 73 years) with myelodysplastic syndromes (MDS), consecutively diagnosed at our center during a 10-year period...
  77. ncbi Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation
    K Ohyashiki
    First Department of Internal Medicine, Tokyo Medical University, Department of Virology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo 160 0023, Japan
    Leuk Lymphoma 42:291-9. 2001
    Myelodysplastic syndromes (MDS) are characterized by cytopenias in the blood and dysplastic features in the hematopoietic cells...
  78. ncbi [Expression of G-CSF and GM-CSF receptors on CD34 positive cells in aplastic anemia and myelodysplastic syndrome patients and its significance]
    Hong Zhi Xu
    Department of Hematology, Provincial Hospital, Shandong University, Jinan 250021, Shandong Province, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 16:1308-11. 2008
    ..of G(M)-CSFR on CD34+ cells in bone marrow of the patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS)...
  79. ncbi Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II
    Jia Wei
    Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 17:111-6. 2009
    ..which belongs to a new subtype of World Health Organization (WHO) classification of myelodysplastic syndrome (MDS) and to screen out the independent immunologic prognostic factors of MDS...
  80. ncbi The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows
    S Mundle
    Rush Cancer Institute, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Int J Hematol 69:152-9. 1999
    The paradox of peripheral cytopenias despite cellular bone marrow (BM) observed in myelodysplastic syndromes (MDS) has been associated with excessive intramedullary apoptosis of hematopoietic cells...
  81. ncbi Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
    Dawn Hershman
    Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 99:196-205. 2007
    ..Although these growth factors support chemotherapy, their long-term safety has not been evaluated. We studied the association between G-CSF use and incidence of leukemia in a population-based sample of breast cancer patients...
  82. ncbi The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Eur J Haematol 79:8-16. 2007
    ..This study investigated sTfR concentrations in ineffective, dysplastic erythropoiesis in myelodysplastic syndrome (MDS).
  83. doi Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature
    Birgitta Swolin
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, 413 45 Goteborg, Sweden
    Ann Hematol 87:467-74. 2008
    ..patients with polycythemia vera (PV) develop a terminal acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)...
  84. ncbi [Study on HFE gene mutations in patients with myelodysplastic syndromes and aplastic anemia]
    Ling Nie
    The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC, Tianjin 300020, China
    Zhonghua Xue Ye Xue Za Zhi 30:223-8. 2009
    To detect the incidence of the HFE gene C282Y and H63D mutations in patients with myelodysplastic syndromes (MDS) and aplastic anemia (AA), and analyze the relationship of these mutations with iron metabolism, and organs impairment from ..
  85. doi International Working Group on MDS cytogenetics: October 2007 meeting report
    Marilyn L Slovak
    Department of Cytogenetics, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, United States
    Leuk Res 32:1329-32. 2008
    The inaugural meeting of the International Working Group on MDS cytogenetics convened 22-23 October 2007 in Chicago, IL...
  86. ncbi Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure
    R R West
    University of Wales College of Medicine, Cardiff, UK
    Blood 95:2093-7. 2000
    Patients with myelodysplastic syndromes (MDS) have high frequencies of cytogenetic abnormalities and evidence is accumulating of associations between exposure history and primary MDS...
  87. ncbi Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group
    Andreas Josting
    First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    J Clin Oncol 21:3440-6. 2003
    To assess the incidence and outcome of secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients with Hodgkin's disease (HD).
  88. ncbi No increase in age-specific incidence of myelodysplastic syndromes
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University of Dusseldorf, Germany
    Haematologica 89:905-10. 2004
    Epidemiological data on myelodysplastic syndromes (MDS) are sparse. However, the available evidence indicates that MDS is among the most common hematologic diseases.
  89. ncbi [Effect of IL-15 on the proliferation and differentiation of CD34+ cells from MDS patients]
    Zhong Lu Ye
    Deparement of Pediatrics, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 21:106-9. 2005
    To explore the effect of IL-15 on proliferation and differentiation of CD34 (+) cells from MDS patients.
  90. ncbi Risk factors of myelodysplastic syndromes: a case-control study
    S S Strom
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 19:1912-8. 2005
    Little is known about the etiology of myelodysplastic syndromes (MDS)...
  91. ncbi Current treatment options: impact of cytogenetics on the course of myelodysplasia
    Naomi Galili
    Radhey Khanna MDS Center, Division of Hematology, University of Massachusetts Medical Center, 364 Plantation Street, Worcester, MA 01605, USA
    Curr Treat Options Oncol 8:117-28. 2007
    The heterogeneity of myelodysplastic syndromes (MDS) has driven the search for unifying biologic and clinical features that would stratify patients into distinct prognostic and therapeutic subgroups...
  92. doi Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes
    Michael Wulfert
    Klinik für Hämatologie, Onkologie und klinische Immunologie, Heinrich Heine Universitat, Dusseldorf, Germany
    Exp Hematol 36:577-86. 2008
    To determine the frequency and spectrum of somatic mutations of mitochondrial DNA (mtDNA) in bone marrow of patients with myelodysplastic syndrome (MDS).
  93. doi Immunophenotype of myeloid granulocytes: a pilot study for distinguishing myelodysplastic syndrome and aplastic anemia by flow cytometry
    M Huang
    Department of Clinical Laboratory, Provincial Hospital affiliated to Shandong University, Jinan City, China
    Int J Lab Hematol 32:275-81. 2010
    It is often difficult to distinguish myelodysplastic syndrome (MDS) from aplastic anemia (AA) because of the considerable clinical, cytologic histologic similarities between these two disorders; however, distinguishing between AA and MDS ..
  94. ncbi Glomerular involvement in myelodysplastic syndromes
    R Bogdanovic
    Institute of Mother and Child Health of Serbia, 8 R Dakica St, 11070 Belgrade, Yugoslavia
    Pediatr Nephrol 16:1053-7. 2001
    Several reports have documented various forms of glomerular diseases in adults with myelodysplastic syndromes (MDS), but similar reports in children are lacking...
  95. ncbi Clinical and morphological features of paediatric myelodysplastic syndromes: a review of 34 cases
    S Polychronopoulou
    Department of Paediatric Haematology Oncology, Aghia Sophia Children s Hospital, Athens, Greece
    Acta Paediatr 93:1015-23. 2004
    The clinical and morphological spectrum of myelodysplastic syndromes (MDS) during childhood has not yet been completely documented...
  96. doi Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006
    Anneclaire J De Roos
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109 1024, USA
    Am J Hematol 85:765-70. 2010
    Myelodysplastic syndromes (MDS) incidence is unclear because of historical lack of population-based registration and possibly because of underdiagnosis...
  97. doi Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia
    Azra Raza
    Department of Medicine, St Vincent s Comprehensive Cancer Center, New York, New York 10011, USA
    Cancer 113:1596-604. 2008
    The treatment of myelodysplastic syndromes (MDS) remains a challenge to the clinician despite recent advances. Many patients will either not respond or will have only limited and/or brief responses to single-agent therapy...
  98. ncbi Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes
    Sindhu Cherian
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Cytometry B Clin Cytom 64:9-17. 2005
    Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic disorders diagnosed using morphologic and clinical findings supported by cytogenetics...
  99. doi Estimation of economic costs associated with transfusion dependence in adults with MDS
    Jennifer R Frytak
    i3 Innovus, Eden Prairie, MN 55344, USA
    Curr Med Res Opin 25:1941-51. 2009
    To examine the economic burden of myelodysplastic syndromes (MDS) and the incremental cost of transfusion dependence.
  100. doi Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group
    Yasuyoshi Morita
    Department of Hematology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Int J Hematol 91:97-103. 2010
    A total of 120 patients with high-risk myelodysplastic syndrome (MDS) and AML progressed from MDS (MDS-AML) were registered in a randomized controlled study of the Japan Adult Leukemia Study Group (JALSG)...
  101. ncbi Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients
    M Dalamaga
    Department of Clinical Biochemistry, Attikon General University Hospital, University of Athens, School of Medicine, Athens, Greece
    J Eur Acad Dermatol Venereol 22:543-8. 2008
    Cutaneous lesions in myelodysplastic syndrome (MDS) may be specific or not and may reveal bone marrow transformation...

Research Grants76

  1. Molecular Pathogenesis of MDS and CMML
    Jaroslaw P Maciejewski; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): In myelodysplastic syndrome (MDS) chromosomal abnormalities play an important diagnostic and prognostic role, pointing towards possible disease-causing pathways...
  2. Jaroslaw P Maciejewski; Fiscal Year: 2014
    ..provided by applicant): Bone marrow failure (BMF) syndromes, including aplastic anemia (AA) and myelodysplasia (MDS) are disorders characterized by hematopoietic progenitor or stem cell failure resulting in deficient production of ..
  3. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Javier Pinilla; Fiscal Year: 2012
    Myelodysplastic syndromes (MDS) are characterized by incompetent hematopoiesis that leads to single or multi-lineage peripheral cytopenias with the development of acute myeloid leukemia (AML) in approximately 30-40% of cases...
  4. Rafael Bejar; Fiscal Year: 2016
    ..aims of this proposal are to: (1) study a clinically annotated cohort of 439 bone marrow samples from patients with MDS to determine if the mutations they carry are associated with common clinical features of MDS and overall patient ..
  5. Myelodysplastic Syndromes: Patterns of Care and Outcomes
    Xiaomei Ma; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The myelodysplastic syndromes (MDS) are a group of clonal proliferative bone marrow disorders that result in dysmyelopoiesis and peripheral blood cytopenias...
  6. Zhijian Qian; Fiscal Year: 2014
    ..The myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cells (HSCs), characterized by ineffective hematopoiesis with a high ..
  7. Anjana Rao; Fiscal Year: 2016
    ..Simultaneously, several labs reported that TET2 mutations are frequently associated with myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and myeloid malignancies such as chronic myelomonocytic leukemia (CMML) and ..
  8. Camille Abboud; Fiscal Year: 2016
    ..dynamic translational cancer research program that focuses specifically on leukemias and myelodysplastic syndromes (MDS)...
  9. Modeling Multi-step Leukemogenesis Nf1 and Kras Mutant Mice
    JENNIFER LAUCHLE; Fiscal Year: 2009
    ..Importantly, many patients with MDS and MPD ultimately evolve into acute leukemia that is refractory to treatment...
  10. BENJAMIN BRAUN; Fiscal Year: 2016
    ..Thus, they have features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN)...
  11. ALEXANDER C MINELLA; Fiscal Year: 2014
    ..These features are characteristics of hematopoietic cells of patients with early-stage myelodysplastic syndromes (MDS)...
  12. Targeting the ROS-p38 MAPK Pathway as a Novel Strategy for Stem Cell Expansion
    GAVIN YONG WANG; Fiscal Year: 2012
    ..pathogenesis of a variety of hematopoietic disorders, including Franconi anemia (FA) and myelodysplastic syndromes (MDS)...
  13. IEX-1 as a potential biomarker for early detection of myelodysplastic syndromes
    Mei X Wu; Fiscal Year: 2012
    ..of IEX-1 (Immediate Early responsive gene X-1) as a biomarker for the early diagnosis of myelodysplastic syndromes (MDS) or its progression to acute myeloid leukemia (AML)...
  14. Comparative Effectiveness: Erythropoietic Stimulating Agents in Treatment of MDS
    Amy J Davidoff; Fiscal Year: 2010
    ..patterns of treatment with erythropoietic stimulating agents (ESA) in patients with myelodysplastic syndromes (MDS), and compare clinical benefits, risks, and costs associated with any ESA use, and different levels of ESA exposure...
  15. Oliver W Press; Fiscal Year: 2015
    ..this treatment for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and lymphomas by targeting radionuclides to neoplastic cells using monoclonal antibodies (Ab) directed at the CD45 ..
  16. LINDSAY MARIE LAFAVE; Fiscal Year: 2014
    ..BAP1 has been found to be mutated and downregulated in human myelodysplastic syndromes (MDS) consistent with BAP1 functioning as a novel tumor suppressor in the hematopoietic compartment...
  17. Matthew J Walter; Fiscal Year: 2015
    ..to identify and characterize genes that contribute to the development and progression of myelodysplastic syndromes (MDS)...
  18. Omar Abdel-Wahab; Fiscal Year: 2015
    ..mutations in ASXL1 were discovered in patients with myeloid malignancies, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and acute myeloid leukemia (AML)...
  19. Third Bone Marrow Failure Disease Scientific Symposium
    Richard M Stone; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Aplastic Anemia &MDS International Foundation 2012 Bone Marrow Failure Disease Scientific Symposium Project Abstract Aplastic anemia (AA), myelodysplastic syndromes (MDS), and paroxysmal ..
  20. WHOLE GENOME SEQUENCING OF MYELODYSPLASTIC SYNDROMES
    Timothy A Graubert; Fiscal Year: 2010
    ..whole genome resequencing to identify genetic changes relevant for the pathogenesis of Myelodysplastic Syndromes (MDS). MDS is an increasingly prevalent clonal hematopoietic disorder that causes significant morbidity and mortality...
  21. Myelodysplastic Syndromes: Previous Exposures, Survival, and Quality of Life
    Xiaomei Ma; Fiscal Year: 2010
    ..The myelodysplastic syndromes (MDS) are a group of clonal proliferative bone marrow disorders resulting in dysmyelopoiesis and peripheral blood ..
  22. p38 MAPK as a therapeutic target in Myelodysplastic syndrome
    Amit Verma; Fiscal Year: 2009
    Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and decreased blood counts...
  23. A model of myelodysplastic syndrome progression and leukemic stem cells
    Yupo Ma; Fiscal Year: 2012
    Myelodysplastic syndromes (MDS) are stem-cell malignancies most frequently seen among elderly patients, resulting in a high annual incidence of approximately 14,000 new cases per year...
  24. Mary Y Armanios; Fiscal Year: 2016
    ..patients have an increased risk for developing hematologic malignancies, specifically myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)...
  25. Dong Er Zhang; Fiscal Year: 2016
    ..mutations in splicing factor-encoded genes in bone marrow failure diseases, such as myelodysplastic syndromes (MDS) and related disorders...
  26. Prediction of Response to Revlimid
    Azra Raza; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Myelodysplastic syndromes (MDS) constitute a group of heterogeneous bone marrow stem cell disorders where no single treatment strategy has been of universal benefit...
  27. David A Williams; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): The inherited bone marrow failure and myelodysplastic syndromes (iBMF/MDS) are a heterogeneous group of disorders that are characterized by impaired hematopoiesis and a propensity to progress to ..
  28. Phase II trial of valproic acid in myelodysplasia
    Peter Klein; Fiscal Year: 2006
    The myelodysplastic syndromes (MDS) are a heterogeneous group of neoplastic hematopoietic stem cell disorders characterized by peripheral blood cytopenias and a proclivity for transformation into acute leukemia...
  29. Laura M Calvi; Fiscal Year: 2016
    ..Aging of the hematopoietic system results in an increased risk of developing cytopenias, Myelodysplastic syndromes (MDS), myeloproliferative disorders and leukemias...
  30. Clinical and Molecular Characterization of Familial Marrow Failure Syndrome
    Akiko Shimamura; Fiscal Year: 2012
    ..disorders characterized by marrow failure, congenital anomalies, and predisposition to myelodysplastic syndromes (MDS)...
  31. CLONALITY IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
    Donald Kufe; Fiscal Year: 1992
    ..of clonal growth and growth factor expression in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)...
  32. System Biology Approach for Signaling Transduction Study of Complex Phenotypes
    Youli Zu; Fiscal Year: 2012
    ..We will use the four myelodysplastic syndromes (MDS) phenotypes as the prototype of disease to test the performance of this package by integrating high-throughput ..
  33. Functional Dissection of Erythroid Differentiation
    Benjamin Ebert; Fiscal Year: 2009
    Myelodysplasic syndromes (MDS) are clonal disorders of ineffective hematopoiesis that commonly progress to acute leukemia. The primary mechanisms underlying aberrant hematopoietic differentiation have not been identified...
  34. Amittha Wickrema; Fiscal Year: 2015
    ..Moreover, in conditions such as myelodysplastic syndromes (MDS), where anemia is the most common presentation and predominant cause of morbidity, the focus has mainly been to ..
  35. A MARIO Q MARCONDES; Fiscal Year: 2014
    ..The proposal is aimed at elucidating the pathophysiology of the myelodysplastic syndromes (MDS). A prominent characteristic of MDS is dysregulation of programmed cell death (apoptosis)...
  36. Merav Socolovsky; Fiscal Year: 2016
    ..aberrant DNA methylation was recently found in the refractory anemias classified as myelodysplastic syndromes (MDS), where demethylation therapy is successful...
  37. Role of AhR During Megakaryopoiesis
    STEPHAN CADET LINDSEY; Fiscal Year: 2011
    ..Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem cell disorders often accompanied by defective megakaryocyte (Mk) development, ..
  38. Daniel Starczynowski; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Myelodysplastic syndromes (MDS) are clonal marrow failure disorders defined by blood cytopenias due to ineffective hematopoiesis, genomic instability, and predisposition to leukemia...
  39. Targeted Therapy of Lyn in Myelodysplastic Syndrome
    SETH JOEL COREY; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Myelodysplastic Syndromes (MDS) are a disorder, increasing in frequency, for which there is poor understanding of its pathophysiology and no curative therapy short of an allogeneic stem cell ..
  40. New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (MDS)
    Hagop Kantarjian; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The incidence of myelodysplastic syndromes (MDS) is likely to increase as the U.S. population ages. Nonetheless, there are no satisfactory treatments...
  41. Vitamin D and Dexamethasone in Myelodysplastic Syndromes
    ROBERT REDNER; Fiscal Year: 2003
    The myelodysplastic syndromes (MDS) represent a heterogeneous group of diseases that manifest themselves as dyspoiesis...
  42. BUTYRIC ACID DERIVATIVES IN MYELOID MALIGNANCIES
    Steven Gore; Fiscal Year: 1999
    Because aberrant terminal differentiation is a prominent feature of myelodysplastic syndromes (MDS), these disorders have been targets of a variety of attempts to effect differentiation using non-cytotoxic agents...
  43. Proteasome Inhibition in Myelodysplastic Syndromes
    Jane Liesveld; Fiscal Year: 2006
    DESCRIPTION (provided by applicant): The myelodysplastic syndromes (MDS) are characterized by cytopenias in one or more hematopoietic lineages as a result of ineffective and dysplastic hematopoiesis...
  44. Genomics of myelodysplastic syndromes
    Timothy Graubert; Fiscal Year: 2009
    The myelodysplastic syndromes (MDS) are a heterogenous group of disorders characterized by clonal expansion of hematopoietic cells. Cytopenias and transformation to acute myeloid leukemia are important sequelae of MDS...
  45. EDWARD PAUL HASTY; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Myelodysplastic syndrome (MDS) is a group of disorders characterized by dysfunctional blood cells that can progress to acute myeloid leukemia (AML)...
  46. ICSBP Function During Myeloid Differentiation
    ELIZABETH ANN EKLUND; Fiscal Year: 2011
    ..First, ICSBP-expression is decreased in bone marrow samples from subjects with myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML)...
  47. Cell signaling as a leukemia biomarker
    JAMES WILLIAM JACOBBERGER; Fiscal Year: 2013
    ..proposal are to develop a system to monitor patients with pre-leukemic conditions like myelodysplastic syndrome (MDS) and myeloid proliferative neoplasms (MPN) for early detection of leukemic transition...
  48. Oliver W Press; Fiscal Year: 2014
    Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) currently kill the majority of afflicted patients despite treatment with combination chemotherapy and hematopoietic cell transplantation (HCT)...
  49. Qishen Pang; Fiscal Year: 2014
    ..proliferation of hematopoietic stem and progenitor (HSC/P) cells, and progression to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)...
  50. Molecular Genetic Investigation of Pediatric Myelodysplastic Syndrome
    David A Williams; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Pediatric Myelodysplastic Syndrome (MDS) is a heterogeneous group of clonal stem cell disorders characterized by varying degrees of cytopenias, and ineffective and dysplastic hematopoiesis...
  51. Margaret A Goodell; Fiscal Year: 2016
    ..found in many pathologic states, and has become of particular interest in the context of myelodysplastic syndrome (MDS)...
  52. Steven D Gore; Fiscal Year: 2015
    ..5AC) with an oral histone deacetylase (HDAC) inhibitor entinostat in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML);a randomized Phase II trial of two schedules of the HDAC inhibitor vorinostat in ..
  53. Regulation of Hematopoietic Progenitors by de novo DNA Methylation
    Margaret Goodell; Fiscal Year: 2011
    ..found in many pathologic states, and has become of particular interest in the context of myelodysplastic syndrome (MDS)...
  54. Flexible and Somatic Mouse Models for Myelodysplastic Syndrome Progression
    Yupo Ma; Fiscal Year: 2009
    Myelodysplastic syndrome (MDS) is, at present, incurable preleukemic disease occurring most frequently among the elderly with about 14,000 new cases per year in the USA...
  55. Development of a Sensitive Theranostic Assay for Myelodysplastic Syndrome
    STEPHANIE POND; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): MDS patients harboring acquired activating mutations in the FLT3 receptor tyrosine kinase tend to progress to acute myeloid leukemia (AML) significantly more rapidly and with higher frequency than ..
  56. The Role of PKR in a Novel IL-3 Signal Transduction Pathway
    William Stratford May; Fiscal Year: 2012
    ..preliminary data indicate that PKR is differentially localized and activated in IPSS high risk compared to low risk MDS patient samples or normal hematopoietic progenitors...
  57. BENJAMIN LEVINE EBERT; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Myelodysplastic syndrome (MDS) is characterized by ineffective hematopoiesis, most commonly of the erythroid lineage, resulting in a phenotype termed refractory anemia...
  58. Twenty-second Annual Fanconi Anemia Research Fund Scientific Symposium
    GROVER CARLTON BAGBY; Fiscal Year: 2010
    ..disease characterized by bone marrow failure, developmental anomalies, a high incidence of myelodysplasia (MDS), acute non-lymphocytic leukemia (AML), solid tumors, and cellular hypersensitivity to cross-linking agents...
  59. 24th Annual Fanconi Anemia Research Fund Scientific Symposium
    GROVER CARLTON BAGBY; Fiscal Year: 2012
    ..hereditary disease characterized by bone marrow failure, developmental anomalies, high incidence of myelodysplasia (MDS), acute non-lymphocytic leukemia (AML), solid tumors, and cellular hypersensitivity to cross-linking agents...
  60. Reactivation of Tumor Suppressor Genes in Breast Cancer by Dietary Supplements as
    Zhongfa Liu; Fiscal Year: 2010
    ..a novel, superior chemotherapeutic strategy for treatment of various leukemia, including myelodysplastic syndrome (MDS) compared to cytotoxic agents...
  61. PEARLIE K BURNETTE; Fiscal Year: 2016
    ..anemia (AA), paroxysmal nocturnal hemaglobinuria (PNH), and a subset of patients with Myelodysplastic Syndrome (MDS)...
  62. Mechanisms of cancer initiation by TRIM32
    Molly F Kulesz-Martin; Fiscal Year: 2012
    ..in human cervical carcinoma, and its downregulation is prognostic for conversion from myelodysplastic syndrome (MDS) to later stages and chronic myeloid leukemia (CML)...
  63. AA&MDSIF Second Bone Marrow Failure Disease Scientific Symposium
    Richard Stone; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Aplastic anemia (AA), the myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) are rare diseases that all result in bone marrow failure...
  64. 5-Azacytidine and MS-275 in Myeloid Malignancies
    Steven Gore; Fiscal Year: 2005
    5-azacytidine (5AC) is a highly active agent for the treatment of myelodysplastic syndromes (MDS, response rate 50 - 60%)...
  65. Model systems for hematologic disorders caused by ribosomal protein deficiency
    George Thomas; Fiscal Year: 2010
    ..the inherited marrow failure syndromes Diamond-Blackfan anemia (DBA) and the 5q- myelodysplastic syndrome (5q- MDS)...
  66. Genetic Basis of Myeloid Neoplasia--Mutagenesis Screens
    A Look; Fiscal Year: 2005
    ..of the genes discovered by this method will have human counterparts that contribute to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), or to one of the congenital neutropenias that predispose to these malignancies...
  67. Proteasome/HDAC Inhibition in Leukemia/MDS; Phase I Trial and Correlative Studies
    Steven Grant; Fiscal Year: 2010
    ..belinostat (PXD-101) and the proteasome inhibitor (PI) bortezomib in patients with refractory AML, high-risk MDS, CML-blast crisis, and ALL...
  68. ROLE OF THE PNH PHENOTYPE IN LEUKEMIC TRANSFORMATION
    Monica Bessler; Fiscal Year: 2005
    ..PNH is frequently found in patients with aplastic anemia (AA) and in patients with myelodysplasia (MDS)...
  69. Development of a Pediatric Mylelodysplastic Syndrome Patient Registry
    DAVID A contact WILLIAMS; Fiscal Year: 2010
    ..is a rare hematopoietic disease characterized by a heterogeneous group of disorders that include primary or de novo MDS, and "secondary MDS" following congenital or acquired bone marrow failure (BMF) syndromes or cytotoxic therapy...
  70. Regulation of PAF Acetylhydrolase Expression by Oxidized Phospholipids
    SUZANNE BARBOUR; Fiscal Year: 2009
    Platelet-activating factor acetylhydrolase (PAFAH) also known as the lipoprotein-associated phospholipase A2 is a calcium-independent acylhydrolase that catabolizes oxidized phospholipids (oxPL) in the oxidized LDL (oxLDL) particle as ..
  71. Nucleophosmin and ribosomal dysfunction in hematologic diseases
    Pier Paolo Pandolfi; Fiscal Year: 2010
    ..Abstract Myelodysplastic syndrome (MDS), similar to a number of other hematologic disorders, is associated with a strong anemia and dyserythropoiesis...
  72. RESEARCH TRAINING IN BLOOD AND VASCULAR BIOLOGY
    Sandor Shapiro; Fiscal Year: 1999
    ..The purpose of our program continues to be the training of MDs and Ph.Ds in basic investigational approaches to problems in hematologic research and vascular biology...
  73. HEALTH OF BLACK AND WHITE NURSING HOME RESIDENTS
    VERONICA ENGLE; Fiscal Year: 2000
    ..All nursing homes now use the Minimum Data Set (MDS) to assess and direct care planning, but it is not known if the MDS can sensitively and specifically address race ..
  74. A Mouse Model of Myelodysplastic Syndrome Progression
    Giuseppina Nucifora; Fiscal Year: 2009
    Myelodysplastic syndrome (MDS) is a fatal hematopoietic clonal disorder with the highest incidence among older people (>60 years). MDS is a complex disease characterized by apparently contradictory coexisting features...